Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer

Molecular targeting therapy is becoming the standard of care for some patients with anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma. Drug-related pneumonitis (DRP) has been identified as an infrequent but potentially severe adverse effect. Herein, we report a 50-year-old woman with A...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xianmeng, Xia, Daqing, Jiang, Xuqin, Cao, Lejie, Ryu, Jay H., Hu, Xiaowen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663455/
https://www.ncbi.nlm.nih.gov/pubmed/36386178
http://dx.doi.org/10.3389/fphar.2022.944685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663455/
https://www.ncbi.nlm.nih.gov/pubmed/36386178
http://dx.doi.org/10.3389/fphar.2022.944685

Ejemplares similares